Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jay Maizes

Pulmonary Disease Atlantis, FL Medical Doctor

NPI 1821045642 CMS profile 263875

5401 S Congress Ave Ste 204, Atlantis, FL 33462

Open in the dashboard

General payments

$6,416

295 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jay Maizes of Atlantis, FL is reported in the CMS Open Payments database as having received $6,416 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,931 73
2024 General $1,395 60
2023 General $1,194 68
2022 General $635 32
2021 General $446 21
2020 General $459 25
2019 General $356 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Maizes
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Jay Maizes were reported at $1,931. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Jay Maizes Pulmonary Disease median Middle half National median
2019 $356 $377 $109–$1,340 $163
2020 $459 $230 $56–$907 $114
2021 $446 $269 $68–$1,072 $132
2022 $635 $390 $100–$1,457 $149
2023 $1,194 $419 $114–$1,659 $160
2024 $1,395 $476 $123–$1,818 $164
2025 $1,931 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,242 67 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $942 38 payments
  3. AstraZeneca Pharmaceuticals LP $755 35 payments
  4. Grifols USA, LLC $409 26 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $374 14 payments
  6. ANI Pharmaceuticals, Inc. $363 13 payments
  7. Inogen, Inc. $248 20 payments
  8. Insmed, Inc. $218 12 payments
  9. Relypsa, Inc. $202 8 payments
  10. Mallinckrodt Hospital Products Inc. $195 5 payments
  11. Other $1,469 57 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,164 287 payments
  2. Education $253 8 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $688 33 payments
  2. OFEV Respiratory $539 22 payments
  3. NUCALA $433 21 payments
  4. Prolastin-C Liquid $383 24 payments
  5. GLASSIA $374 14 payments
  6. PURIFIED CORTROPHIN GEL $337 12 payments
  7. FASENRA $336 11 payments
  8. BREZTRI $308 16 payments
  9. OFEV Respiratory $274 11 payments
  10. DUPIXENT $202 5 payments
  11. Other $3,063 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,742

Median for Pulmonary Disease: 936

Drug cost

$1,117,546

Median for Pulmonary Disease: $487,987

Branded share of claims

73.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 37 $477,124
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 297 $296,630
Breo Ellipta Fluticasone/Vilanterol Brand 144 $82,539
Spiriva Respimat Tiotropium Bromide Brand 88 $75,504
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 52 $46,289
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 36 $24,456
Incruse Ellipta Umeclidinium Bromide Brand 49 $18,631
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 29 $17,412
Atrovent Hfa Ipratropium Bromide Brand 28 $13,832
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 75 $13,414

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$195,657

Medicare's payments for the services billed

Medicare patients

703

Average age 77

Services billed

2,631

373 women, 330 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 57%
Ischemic heart disease 56%
Arthritis 54%
Heart failure 49%
Diabetes 48%
Chronic kidney disease 45%
Atrial fibrillation 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $275
$275 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $166
$166 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $157
$157 37 —
Zemaira
  • Relypsa, Inc. $111
$111 — —
DUPIXENT
  • GENZYME CORPORATION $62
  • Regeneron Healthcare Solutions, Inc. $34
$95 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record